From the Department of Health Research and Policy, Stanford University School of Medicine (M.M.M., V.L., S.N.G.) and Stanford Law School (M.M.M.) - both in Stanford, CA.
N Engl J Med. 2018 Jun 7;378(23):2202-2211. doi: 10.1056/NEJMsa1713258.
Background Sharing of participant-level clinical trial data has potential benefits, but concerns about potential harms to research participants have led some pharmaceutical sponsors and investigators to urge caution. Little is known about clinical trial participants' perceptions of the risks of data sharing. Methods We conducted a structured survey of 771 current and recent participants from a diverse sample of clinical trials at three academic medical centers in the United States. Surveys were distributed by mail (350 completed surveys) and in clinic waiting rooms (421 completed surveys) (overall response rate, 79%). Results Less than 8% of respondents felt that the potential negative consequences of data sharing outweighed the benefits. A total of 93% were very or somewhat likely to allow their own data to be shared with university scientists, and 82% were very or somewhat likely to share with scientists in for-profit companies. Willingness to share data did not vary appreciably with the purpose for which the data would be used, with the exception that fewer participants were willing to share their data for use in litigation. The respondents' greatest concerns were that data sharing might make others less willing to enroll in clinical trials (37% very or somewhat concerned), that data would be used for marketing purposes (34%), or that data could be stolen (30%). Less concern was expressed about discrimination (22%) and exploitation of data for profit (20%). Conclusions In our study, few clinical trial participants had strong concerns about the risks of data sharing. Provided that adequate security safeguards were in place, most participants were willing to share their data for a wide range of uses. (Funded by the Greenwall Foundation.).
分享参与者水平的临床试验数据具有潜在的益处,但对研究参与者可能受到的潜在伤害的担忧,导致一些制药赞助商和研究人员敦促谨慎行事。对于临床试验参与者对数据共享风险的看法,人们知之甚少。
我们在美国三个学术医疗中心的多样化临床试验中,对 771 名当前和近期参与者进行了结构化调查。通过邮件(350 份完成的调查)和诊所候诊室(421 份完成的调查)分发调查问卷(总体回复率为 79%)。
不到 8%的受访者认为数据共享的潜在负面影响超过了好处。共有 93%的人非常或有些可能允许自己的数据与大学科学家共享,82%的人非常或有些可能与营利性公司的科学家共享。愿意共享数据与数据的使用目的没有明显的差异,除了较少的参与者愿意为诉讼目的共享数据。受访者最担心的是数据共享可能会使其他人不太愿意参加临床试验(37%非常或有些担心),数据将被用于营销目的(34%),或者数据可能被盗(30%)。对歧视(22%)和数据为利润而被利用(20%)的担忧则较少。
在我们的研究中,很少有临床试验参与者对数据共享的风险有强烈的担忧。只要有充分的安全保障措施,大多数参与者都愿意为广泛的用途共享他们的数据。(由 Greenwall 基金会资助)。